Moreover, the 36-month beta value for GRI is -1.67. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for GRI is 0.73M and currently, short sellers hold a 34.46% of that float. On May 02, 2025, GRI’s average trading volume was 357.82K shares.
GRI) stock’s latest price update
The stock of GRI Bio Inc (NASDAQ: GRI) has increased by 7.14 when compared to last closing price of 1.82.Despite this, the company has seen a gain of 16.77% in its stock price over the last five trading days. globenewswire.com reported 2025-04-16 that LA JOLLA, CA, April 16, 2025 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been selected for poster presentation in a poster discussion session at the 2025 ATS International Conference being held May 18-21, 2025 in San Francisco, CA. Details of the presentation are as follows: Title: Inactivation of iNKT Cells After the Inflammatory Phase Leads to Significant Inhibition of Fibroblast Activation and Fibrosis in a Model of Pulmonary Fibrosis Poster Board Number: 810 Presenter: Marc Hertz, PhD, Chief Executive Officer of GRI Bio Session: D21 – IMMUNOLOGICAL INSIGHTS IN LUNG INFLAMMATION AND REPAIR Date and Time: Wednesday, May 21, 2025 from 8:15-10:15 AM PT Location: Room 2022/2024 (West Building, Level 2), Moscone Center For more information about the 2025 ATS International Conference, please visit the conference website, here.
GRI’s Market Performance
GRI’s stock has risen by 16.77% in the past week, with a monthly drop of -3.47% and a quarterly drop of -82.53%. The volatility ratio for the week is 13.35% while the volatility levels for the last 30 days are 22.23% for GRI Bio Inc The simple moving average for the past 20 days is 25.12% for GRI’s stock, with a -80.41% simple moving average for the past 200 days.
Analysts’ Opinion of GRI
Many brokerage firms have already submitted their reports for GRI stocks, with H.C. Wainwright repeating the rating for GRI by listing it as a “Buy.” The predicted price for GRI in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on December 09, 2024 of the previous year 2024.
GRI Trading at -55.98% from the 50-Day Moving Average
After a stumble in the market that brought GRI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.16% of loss for the given period.
Volatility was left at 22.23%, however, over the last 30 days, the volatility rate increased by 13.35%, as shares surge +16.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -78.36% lower at present.
During the last 5 trading sessions, GRI rose by +16.77%, which changed the moving average for the period of 200-days by -93.25% in comparison to the 20-day moving average, which settled at $1.5585. In addition, GRI Bio Inc saw -86.15% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for GRI
The total capital return value is set at -2.01. Equity return is now at value -382.57, with -188.80 for asset returns.
Based on GRI Bio Inc (GRI), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -72.36.
Currently, EBITDA for the company is -8.23 million with net debt to EBITDA at 0.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.43.
Conclusion
To wrap up, the performance of GRI Bio Inc (GRI) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
